Gene Therapy Safety In Cardiovascular Disease Defended at ACC
This article was originally published in The Gray Sheet
Executive SummaryFDA's decision to place four gene therapy trials sponsored by Vascular Genetics on hold the week of Feb. 28 did not result from the non-reporting of patient deaths, according to lead investigator Jeff Isner, MD, St. Elizabeth's Medical Center, Boston.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.